Development of an organ-on-a-chip model of polycystic kidney disease for testing new therapies
PKD is a genetic disorder where fluid-filled sacs called cysts form in the kidneys, affecting their function over time and often leading to kidney failure. Autosomal dominant PKD (ADPKD), which means that if a parent has PKD, there's a 50% chance that their child will inherit the faulty gene and develop kidney cysts, is the most common form of PKD, affecting 13 million people worldwide.
Martin and his team will develop an organ-on-a-chip (a bioengineered device consisting of living cells grown within a controlled environment designed to replicate the behaviour of organs in the body) model of ADPKD.
In collaboration with a commercial company, who will use gene-editing technology to make cells with the most common gene faults seen in patients with ADPKD, Martin and the team will then grow the cells within their organ-on-a-chip model.
This is a promising option for testing therapies as it allows researchers to study how potential treatments may affect organs, providing valuable information for developing and refining new therapies.
What this might mean for patients
This novel technology has huge potential to support research and speed up the development and testing of new therapies for ADPKD.
“We are very pleased to have this funding from Kidney Research UK to start the development of an organ-chip model of polycystic kidney disease. We hope that this emerging technology will stimulate the delivery of successful treatments for people with this disease.” Professor Martin Knight
Latest research news
Understanding the link between genetics and the immune system in the development of idiopathic nephrotic syndrome
Exploring the role of BK virus in kidney transplant patients’ cancer risk: a World Cancer Day conversation with Dr Simon Baker
Have you been diagnosed with kidney disease?
Request your free Kidney Kit today.
You'll find tips and support from kidney patients, delicious recipes, simple exercise plans and more.